Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAZTIA XT vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary arteries and peripheral arterioles, and reduction of myocardial contractility and heart rate.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Hypertension (FDA-approved),Chronic stable angina (FDA-approved),Variant angina (FDA-approved),Atrial fibrillation or atrial flutter (rate control, off-label),Supraventricular tachycardia (off-label)
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Oral, 120 mg or 180 mg once daily. For hypertension, initiate at 120 mg once daily; for angina, initiate at 180 mg once daily. Maximum dose: 360 mg once daily.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
3-5 hours (immediate-release) for diltiazem; after TAZTIA XT extended-release, effective half-life is approximately 7-9 hours due to prolonged absorption. Clinical context: steady state achieved in 3-5 days.
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Hepatic via CYP3A4; active metabolite (desacetyldiltiazem).
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Renal (approximately 60% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion), biliary/fecal (approximately 30-35%)
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
70-80% primarily to albumin; also to alpha-1-acid glycoprotein
92-98% bound primarily to albumin.
3.1-5.3 L/kg (central compartment); large Vd indicates extensive tissue distribution, consistent with high lipophilicity and cardiac/vascular tissue binding.
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
Oral (extended-release): approximately 35-60% due to extensive first-pass hepatic metabolism (cytochrome P450 3A4) with significant interindividual variability. Food may increase bioavailability by up to 20%.
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
No specific dose adjustment recommended for mild to moderate renal impairment. Use caution in severe renal impairment (Cr Cl <30 m L/min); consider starting at lower dose and titrate slowly.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
Child-Pugh Class A or B: No specific adjustment, but use caution. Child-Pugh Class C: Contraindicated.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Safety and efficacy not established; no pediatric dosing guidelines available.
Safety and efficacy not established; use is not recommended in pediatric patients.
Start at lower end of dosing range (120 mg once daily) due to increased systemic exposure; titrate slowly based on response and tolerability.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
No FDA boxed warning specific to TAZTIA XT; however, the drug class (calcium channel blockers) may have warnings for increased risk of cardiovascular events in certain populations.
No FDA black box warning.
Heart failure: May worsen symptoms due to negative inotropic effects.,Bradycardia and heart block: Risk especially in elderly or with other AV nodal blockers.,Hypotension: Especially with rapid dose escalation.,Abrupt withdrawal: May cause rebound angina or hypertension.,Hepatic impairment: Reduced metabolism may require dose adjustment.,Concomitant use with beta-blockers: Increased risk of bradycardia and heart block.
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Sick sinus syndrome (except with functioning pacemaker),Second- or third-degree AV block (except with pacemaker),Hypotension (systolic <90 mm Hg),Acute myocardial infarction or pulmonary congestion,Known hypersensitivity to diltiazem,Concurrent use with ivabradine
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase diltiazem plasma concentrations, elevating risk of bradycardia and hypotension. No other significant food interactions. Administer with or without food.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
TAZTIA XT (diltiazem) is classified as FDA Pregnancy Category C. In first trimester, animal studies have shown embryofetal toxicity (skeletal abnormalities, fetal mortality) at doses ≥5 times maximum human dose. No adequate human studies in pregnant women; potential risk cannot be ruled out. In second and third trimesters, use may cause uteroplacental hypoperfusion due to maternal hypotension, potentially leading to fetal hypoxia and growth restriction. Case reports associate with preterm labor and low birth weight. Avoid use during pregnancy unless benefit outweighs risk.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Diltiazem is excreted into breast milk at low concentrations. A study reported milk-to-plasma (M/P) ratio of approximately 0.8-1.0. Estimated infant dose is <1% of maternal weight-adjusted dose, considered clinically insignificant. However, due to potential for adverse effects (hypotension, bradycardia) in neonates, caution advised. American Academy of Pediatrics considers diltiazem compatible with breastfeeding. Monitor infant for signs of bradycardia or hypotension.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
No standard dosing adjustments established for pregnancy. However, pregnancy-induced physiological changes (increased plasma volume, renal clearance, and hepatic metabolism) may reduce diltiazem plasma concentrations. Monitor therapeutic effect and consider dose titration based on blood pressure response and heart rate. Limited data suggest that higher doses may be required. Adjust dose cautiously to avoid maternal hypotension, which could compromise uteroplacental perfusion.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
TAZTIA XT is a once-daily extended-release formulation of diltiazem (240 mg, 300 mg, 360 mg). Use for hypertension or chronic stable angina. Doses >360 mg are not recommended. Do not crush or chew; the matrix delivery system can cause bezoars. Avoid use in sick sinus syndrome without a pacemaker, second- or third-degree AV block, or hypotension (SBP <90 mm Hg). Monitor for bradycardia and peripheral edema. Abrupt withdrawal may exacerbate angina. Contraindicated with IV beta-blockers or in patients with atrial fibrillation/flutter with accessory bypass tract (e.g., WPW).
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
Take TAZTIA XT once daily at approximately the same time every day, with or without food.,Swallow the capsule whole; do not crush, chew, or open it. The empty shell may appear in stool.,Avoid grapefruit and grapefruit juice as it can increase diltiazem levels and risk of side effects.,Do not suddenly stop taking this medication without consulting your doctor, as chest pain or heart attack may worsen.,Report symptoms like slow heartbeat, dizziness, fainting, or swelling of the ankles/feet.,Limit alcohol intake as it can increase dizziness and lower blood pressure.,Warn about interactions with beta-blockers, digoxin, statins, and CYP3A4 inhibitors/inducers.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAZTIA XT vs ADALAT CC, answered by our medical review team.
TAZTIA XT is a Calcium Channel Blocker that works by Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary arteries and peripheral arterioles, and reduction of myocardial contractility and heart rate.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAZTIA XT and ADALAT CC depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAZTIA XT is: Oral, 120 mg or 180 mg once daily. For hypertension, initiate at 120 mg once daily; for angina, initiate at 180 mg once daily. Maximum dose: 360 mg once daily.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TAZTIA XT and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TAZTIA XT is classified as Category C. TAZTIA XT (diltiazem) is classified as FDA Pregnancy Category C. In first trimester, animal studies have shown embryofetal toxicity (skeletal abnormalities, fetal mortality) at dos. ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.